This is a repository copy of *Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/172437/

Version: Published Version

**Article:**
Taprogge, J., Wadsley, J. orcid.org/0000-0002-1499-1277, Miles, E. et al. (1 more author) (2021) Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy. Clinical Oncology, 33 (2). pp. 131-136. ISSN 0936-6555

https://doi.org/10.1016/j.clon.2020.12.002

---

**Reuse**
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:
https://creativecommons.org/licenses/

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy

J. Taprogge *, J. Wadsley †, E. Miles ‡, G.D. Flux §

* National Radiotherapy Trials Quality Assurance (RTTQA) Group, Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK
† The Institute of Cancer Research, London, UK
‡ Weston Park Hospital, Sheffield, UK
§ National Radiotherapy Trials Quality Assurance (RTTQA) Group, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK
¶ Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK

Received 1 October 2020; received in revised form 6 November 2020; accepted 2 December 2020

Abstract

Multicentre clinical trials involving a dosimetry component are becoming more prevalent in molecular radiotherapy and are essential to generate the evidence to support individualised approaches to treatment planning and to ensure that sufficient patients are recruited to achieve the statistical significance required. Quality assurance programmes should be considered to support the standardisation required to achieve meaningful results. Trials should be designed to ensure that dosimetry results from image acquisition systems across centres are comparable by incorporating steps to standardise the methodologies used for the quantification of images and dosimetry. Furthermore, it is essential to assess the expertise and resources available at each participating site prior to trial commencement. A quality assurance plan should be drawn up and training provided if necessary. Standardisation of quantification and dosimetry methodologies used in a trial are essential to ensure that results from different centres may be collated. In addition, appropriate uncertainty analysis should be carried out to correct for differences in methodologies between centres. Recommendations are provided to support dosimetry studies based on the experience of several previous and ongoing multicentre trials.

Key words: Dosimetry; molecular radiotherapy; multicentre trial; quality assurance

Introduction

Most molecular radiotherapy (MRT) treatments are given with a fixed activity administration of radioisotope, accepting that this will lead to a wide range of absorbed doses delivered both to tumours and to organs at risk. Patient dosimetry is seldom carried out either to predict or verify the radiation doses delivered. This is in marked contrast to external beam radiotherapy (EBRT) and brachytherapy [1]. As MRT becomes recognised as a form of systemic radiotherapy rather than conventional chemotherapy, the prospect of personalised treatment planning and optimisation based on patient dosimetry must be considered. Due to radiobiological factors, in particular the range of radiation emissions, relative biological effectiveness, heterogeneous dose distribution [2] and dose rate effects [3], absorbed doses delivered from MRT cannot be directly correlated to, for example, the absorbed dose delivered from a 2 Gy per fraction course of EBRT. Treatment regimens therefore cannot be readily adapted from conventional protocols used for EBRT. Single centres are seldom able to recruit sufficient patients to achieve the statistical significance required to report on study end points [4,5]. Large prospective, randomised, multicentre studies are therefore required to show the value of personalised treatment planning in MRT [6].
The Evidence for Dosimetry

The potential for dosimetry-based treatment planning has been shown for many therapy procedures [6]. Correlations between absorbed doses and clinical outcomes following MRT have been reported for several radiopharmaceuticals in a single-centre clinical studies, in aid of the European Commission's multicentre trials incorporating dosimetry [8], that mean tumour absorbed doses correlated with improved progression-free survival after 131I-tositumomab radioimmunotherapy. Wierts et al. [9] used pre-therapy 124I positron emission tomography/computed tomography (PET/CT) lesion dosimetry in thyroid cancer patients treated with a fixed activity of 131I-Nal and observed a dose–response relationship for thyroid remnants and metastases. A correlation of absorbed dose with successful ablation was also shown for thyroid cancer treated with radioiodine [10]. Ivan et al. [11] found a significant correlation between tumour absorbed doses and tumour shrinkage for pancreatic neuroendocrine tumours treated with 177Lu-DOTATATE. Violet et al. [12] observed a significant correlation between whole-body tumour dose and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617. Barone et al. [13] showed that kidney toxicity after 90Y-DOTATOC therapy is absorbed dose dependent.

Multicentre Clinical Trials Incorporating Dosimetry

Although a large number of clinical trials for new and established radiopharmaceuticals have implemented dosimetry, a recent survey found that MRT practice across Europe varies significantly, especially with respect to the implementation of personalisation treatment based on dosimetry [1]. Collation of results from multiple centres in MRT dosimetry trials requires standardised quantitative single photon emission computed tomography/(computed tomography) SPECT/(CT) acquisitions [14]. In recent years, significant efforts have been made to improve quantification for gamma camera imaging [15–17] and work has started on the standardisation of quantification in MRT. Zimmerman et al. [18] carried out an international comparison of the activity measurement of 177Lu. In a later study, they evaluated the accuracy and reproducibility of activity quantification of planar and SPECT imaging in a multicentre setting with an IAEA phantom study for 133Ba, which was used as a surrogate for 131I [19]. Peters et al. [20] carried out phantom measurements as part of a multi-vendor and multicentre study to assess the quantitative accuracy and inter-system variability of SPECT/CT systems. Both Zimmerman et al. [18,19] and Peters et al. [20] found that absolute SPECT quantification in a multicentre, multinational setting is feasible, but that standardisation of image acquisition, reconstruction parameters and processing is key. Wevrett et al. [21] carried out an international inter-comparison exercise for quantitative imaging of 177Lu to investigate consistency between clinical sites. Gregory et al. [22] and Taprogge et al. [23] established networks of centres able to carry out standardised radioiodine activity quantification.

Hanscheid et al. [24] carried out an international, prospective, controlled, randomised study of radioiodine ablation for differentiated thyroid cancer to compare stimulation with recombinant human thyroid stimulating hormone and thyroid hormone withdrawal. Standardised acquisition and processing protocols were used and dosimetry results calculated at a central dosimetry hub. Sundlov et al. [25] carried out a phase II, multicentre, prospective clinical trial using 177Lu-DOTATATE to treat metastatic neuroendocrine tumours in two centres in Sweden.

Recent examples of multicentre MRT clinical trials that involved standardisation of the acquisition and reconstruction parameters with centralised dosimetry are SEL-I-METRY [22,26,27] and MEDIRAD [23]. SEL-I-METRY (EudraCT no. 2015-002269-47) is a phase II clinical trial to investigate the potential of selumetinib in resensitising patients with advanced iodine refractory differentiated thyroid cancer to radioiodine. Uniquely, the SEL-I-METRY trial implemented a quality assurance programme in association with the UK Radiotherapy Trials Quality Assurance (RTTQA) Group to achieve standardisation across the centres in the trial. MEDIRAD is a European Commission Horizon 2020-funded project. Work package 3 (WP3) within MEDIRAD aims to measure the range of absorbed doses delivered to healthy organs from radioiodine ablation of thyroid cancer. A linked prospective observational study in the UK (INSPIRE, NCT04391244) is at the stage of initial recruitment and currently under development to allow multicentre participation.

Recommendations for Molecular Radiotherapy Dosimetry Multicentre Clinical Trials

Multicentre dosimetry trials require careful planning to ensure that data can be collected, stored and directly compared. Standardisation of image quantification and dosimetry methods with appropriate uncertainty analysis is essential. Systematic or random errors in the quantification, outlining and dosimetry calculations due to imperfect equipment calibrations and differences in processing of data may lead to large uncertainties in the calculated absorbed doses [28]. This could potentially result in a dose–response relationship not being detected or a bias of the data used for the analysis of end points of the clinical trial. Data transfer and storage must be set up to ensure that essential information stored in DICOM tags and non-DICOM data are available for dosimetry processing and review of data as part of a centralised quality assurance programme. The following recommendations are provided to facilitate the successful preparation and running of multicentre MRT studies that incorporate dosimetry, based on the experience of the multicentre SEL-I-METRY and MEDIRAD trials in the UK and mainland Asia.
Europe. These recommendations are generated with the guidance and extensive experience of radiotherapy quality assurance for multinational EBRT trials.

**Trial Quality Assurance Programme**

Recommendation 1: MRT clinical trials involving a component of dosimetry should incorporate a clinical trials quality assurance programme similar to that in place for EBRT.

Clinical trials quality assurance programmes help to ensure that trial data are collected and documented following the trial protocol, good clinical practice and other relevant guidance [29–31]. For MRT clinical trials involving dosimetry, the trial quality assurance should consist of a set of planned, systematic activities to minimise bias due to variations in the dosimetry results from different centres. This should include a site set-up or facility questionnaire and standard operating procedures (SOPs) for site set-up and dosimetry calculations [32]. Examples of site set-up SOPs were published by Gregory et al. [22] in the supplementary material. Furthermore, trial monitoring activities should be defined to ensure adherence to trial protocols at all stages throughout the clinical trial. Protocol deviations from SOPs can be minimised by a case-by-case check of the imaging and reconstruction parameters at a central dosimetry hub [33].

Although clinical trials quality assurance programmes are routine practice in EBRT [34,35], through the Global Quality Assurance of Radiation Therapy Clinical Trials Harmonization Group, RTQA [36] and the Radiotherapy Trials Quality Assurance (RTTQA) Group in the UK, further work is required to implement similar quality assurance programmes in all MRT dosimetry clinical trials. MRT can benefit from the experience gathered in EBRT regarding the set-up and running of multicentre clinical trials involving dosimetry.

**Site Set-up/Facility Questionnaires**

Recommendation 2: Communication should be facilitated between key staff at each centre to promote sharing of experience and resources.

The expertise and resources available at each centre, including medical physics support, experience with MRT dosimetry, gamma camera availability and ancillary equipment required (i.e. radionuclide calibrators) should be assessed with site set-up/facility questionnaires. The questionnaire should identify key local personnel/staff in the multiprofessional team, including a named medical physicist to assist with site set-up measurements, quality control procedures and data handling. All key local personnel/staff should be informed about progress of essential stages in the set-up and running of the clinical trial through regular communications and conference calls. The responses from the questionnaire will identify centres or individuals that may require further training or support for the site set-up measurements at each centre.

**Standardisation of Imaging Acquisition Protocols**

Recommendation 3: Image acquisition and dosimetry protocols should be standardised as far as reasonably practicable allowing for differences in local availability of resources such as SPECT or SPECT/CT systems.

Absorbed dose calculations require serial imaging over several days following therapy. Patients may therefore be asked to make multiple return visits to hospital for further imaging, which can also have resource implications for nuclear medicine departments in terms of both staff and equipment time. In contrast to EBRT, dosimetry procedures are currently often not reimbursed. The requirement for significant additional imaging can therefore increase the costs of academic trials. These factors stress the need for high-quality studies to justify the additional resource requirements to acquire dosimetric information.

**Standardisation of Quantitative SPECT in a Multicentre Setting**

Recommendation 4: Gamma camera calibration methodologies and image acquisition and reconstruction protocols should be standardised across clinical trials.

Site set-up measurements are essential for clinical studies involving quantitative imaging. These may include system volume sensitivity calibrations, partial volume corrections and dead-time characterisation. System volume sensitivity is defined as the system’s count-rate for a uniform concentration of activity. SPECT recovery coefficients are necessary to correct the observed activity concentration in tomographic imaging for partial-volume and resolution effects [37]. Dead-time factors are applied to correct the observed count-rate of the system for count losses due to detector paralysis at high imaged activity levels.

Experience from multicentre MRT clinical trials [22,23] have shown that such measurements may need to be adapted locally based on radiation protection guidance in different countries and centres. It is essential to ensure that the complexity and time required for such measurements are adapted as necessary, particularly for centres with limited resources.

National metrology institutes play a key role in EBRT to ensure delivery of accurate absorbed doses. Accurate activity measurements are essential for MRT absorbed dose calculations. Traceability of activity measurements is currently not an essential requirement in many countries, but will play an important role to achieve comparable dosimetry results from different centres [14].

**Logistics of Data Transfer**

Recommendations 5: Appropriate data transfer facilities for both image DICOM data and associated non-DICOM data collected on case report forms should be established and validated before the clinical trial commences.

DICOM data from the serial imaging of patients and associated non-DICOM data, including injected activities and injection times and dates, will potentially have to be
transferred from the participating centres to a centralised dosimetry hub for the dosimetry calculations. Validation of imaging DICOM and associated non-DICOM data transfer before the trial starts is an essential requirement. Possible options for the transfer of DICOM data are image databases and informatics software platforms, such as KHEOPS [38] or XNAT [39], or the use of file sharing services approved for such data transfer. Long-term availability and support of such a service must be ensured.

Patient data must be pseudoanonymised and data encryption should be ensured prior to data upload to these services subject to the respective data protection regulations, such as the General Data Protection Regulation (GDPR). DICOM tags required for the dosimetry processing may be subject to deletion as part of the pseudoanonymisation process. Tests should be included in the data transfer validation to identify missing DICOM tags. Furthermore, DICOM tags for injection times and administered activities are often not populated.

Data transfer methods of non-DICOM data, including case report forms, must be agreed upon prior to the start of the trial to ensure that data missing in the DICOM tags are available at the centralised dosimetry hub.

**Dosimetry Calculations and Collation of Results**

Recommendations 6: Dosimetry methodologies including uncertainty analysis should either be standardised across centres or carried out at a central dosimetry hub.

For a multicentre clinical trial, dosimetry calculations may be carried out at a centralised dosimetry hub or at the individual local centre. Local data processing requires strict standardisation and appropriate uncertainty estimation [40] of all steps involved in the dosimetry calculations to allow for results to be compared. A central dosimetry hub can help to reduce the risk of bias that may be introduced when data are processed locally. This risk may be mitigated if local dosimetry centres follow common SOPs for all steps involved in the dosimetry calculations. Dosimetry data should in any case be centrally reviewed following the quality assurance procedures drawn up at the beginning of the study. Local data processing and/or dosimetry calculations can potentially reduce the workload at the central dosimetry or quality assurance hub.

Uncertainty analysis is particularly important in MRT because of the current lack of standardisation and the large uncertainties involved in the image processing steps due to outlining and quantification. Dosimetry methodologies must be agreed upon and if different software packages are used, validation should be carried out to ensure that results can be compared. Commercially available software packages are increasingly available, although software developed in-house may be required, based on the dosimetry application. Quality assurance on the different systems should be carried out to provide evidence that the outputs are comparable.

An essential step in dosimetry calculations is often the outlining of lesions and organs-at-risk. Studies have shown that the inter-operator variability of volume delineation can have a significant impact on the absorbed dose calculations [13,41] and, therefore, the ability to identify dose–response relationships if that is a trial end point.

**Future Directions**

Initial studies have shown that inter-system variability for a given vendor and camera type is low if acquisition and reconstruction protocols are standardised across centres so that it may be possible to use the same calibration and correction factors [19,20,22,23]. System parameters including sensitivity, partial-volume effect and dead-time correction could be measured on a number of systems for each vendor and camera type to establish a quantitative imaging database for gamma cameras. This would allow for widespread expansion of the existing imaging network without the requirement of complex site set-up measurements. Further measurements are required in large-scale multicentre settings to verify those initial results.

Nevertheless, the use of global calibration factors from a database of calibration measurements would require centre validation measurements to ensure that results from different centres can be combined and to test the full-dosimetry chain [4,42].

**Conclusions**

Large-scale multicentre clinical trials are essential to investigate the potential for personalised treatment planning in MRT. Trials require careful planning to ensure that end points of the trial can be achieved. To encourage patient participation, optimised and accurate dosimetry protocols must be established. Expertise and resources at participating sites must be evaluated and training provided if necessary. Standardisation of quantification and dosimetry together with appropriate uncertainty analysis are key to allow for collation of results across multiple centres. These steps will facilitate the development of the networks required to develop personalised treatment planning for MRT, as is routine for EBRT and brachytherapy.

**Conflicts of Interest**

J. Taprogge and G.D. Flux report grants from the Euratom research and training programme 2014–2018 and the National Institute for Health Research (NIHR) and funding from the National Health Service to the NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research and NIHR Royal Marsden Clinical Research Facility during the conduct of the study. J. Wadsley reports grants and personal fees from AstraZeneca, grants and personal fees from Sanofi-Genzyme, during the conduct of the study; personal fees from AAA, personal fees from Eisai, personal fees from Lilly, personal fees from Roche, personal fees from Celgene, personal fees from Novartis, personal fees from Ipsen, outside the submitted work.
Acknowledgements

National Health Service funding was provided to the National Institute for Health Research Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research. The MEDIRAD project has received funding from the Euratom research and training programme 2014–2018 under grant agreement no 755523. The National Radiotherapy Trials Quality Assurance Group is funded by the NIHR. We acknowledge infrastructure support from the NIHR Royal Marsden Clinical Research Facility Funding. This report is independent research funded by the NIHR. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care.

References

[1] Sjögreen Gleiser K, Spezi E, Solny P, Gabina PM, Cicone F, Stokke C, et al. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Phys 2017;4(1):28.
[2] O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000;41(3):538–547.
[3] Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 2003;18(1):89–97.
[4] Taprogge J, Leek F, Flux GD. Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imag 2019;63(3):271–277.
[5] European Medicines Agency. Topic E9 Note for guidance on statistical considerations in the design of clinical trials 1998. CPMP/ICH/363/96 [Internet]. Available at: www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials.
[6] Stokke C, Gabina PM, Solny P, Cicone F, Sandstrom M, Gleiser KS, et al. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Phys 2017(4):1:27.
[7] Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleiser KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging 2014;41(10):1976–1988.
[8] Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy. J Nucl Med 2014;55(7):1047–1053.
[9] Wiertz R, Brans B, Havekes B, Kemering GK, Halders SG, Schaper NN, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. J Nucl Med 2016;57(7):1027–1032.
[10] Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imag 2010;37(2):270–275.
[11] Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med 2015;56(2):177–182.
SELIMETRY: protocol for a multicentre UK single arm phase II trial. BMC Cancer 2019;19(1):582.

[27] Wadsley J, Gregory R, Flux G, Newbold K, Du Y, Moss L, et al. SELIMETRY- a multicentre I-131 dosimetry trial: a clinical perspective. Br J Radiol 2017;90(1073):20160637.

[28] Gilbert ES. The impact of dosimetry uncertainties on dose-response analyses. Health Phys 2009;97(5):487–492.

[29] de Balincourt C, Lacombe D, Coens C, den Dulk M, Machiels J-P, Weber D, et al. Multidisciplinary quality assurance and control in oncological trials: perspectives from European Organisation for Research and Treatment of Cancer (EORTC). Eur J Cancer 2017;86:91–100.

[30] Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A, Fairchild A. Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting. Radiother Oncol 2011;100(1):150–156.

[31] Weber DC, Tomsej M, Melidis C, Hurkmans CW. QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 2012;105(1):4–8.

[32] Sajdak R, Trembath L, Thomas KS. The importance of standard operating procedures in clinical trials. J Nucl Med Technol 2013;41(3):231–233.

[33] Blumenstein BA, James KE, Lind BK, Mitchell HE. Functions and organization of coordinating centers for multicenter studies. Control Clin Trials 1995;16(2, Suppl.):4–29.

[34] Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran Jr WJ, et al. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials–report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 2012;83(3):782–790.

[35] Ibbott G, Haworth A, Followill D. Quality assurance for clinical trials. Front Oncol 2013;3(311):1–11.

[36] Melidis C, Bosch WR, Izewska J, Fidarova E, Zubizarreta E, Ishikura S, et al. Radiation therapy quality assurance in clinical trials–Global Harmonisation Group. Radiother Oncol 2014;111(3):327–329.

[37] Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3(3):299–308.

[38] Kheops Inc. Kheops DICOM-compliant image archive [Internet]. 2019 [cited 12 August 2020]. Available from: http://kheops.online.

[39] Marcus DS, Olsen TR, Ramaratnam M, Buckner RL. The Extensible Neuroimaging Archive Toolkit: an informatics platform for managing, exploring, and sharing neuroimaging data. Neuroinformatics 2007;5(1):11–34.

[40] Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glätting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imag 2018;45(13):2456–2474.

[41] Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imag 2010;37(2):212–225.

[42] Kron T, Haworth A, Williams I. Dosimetry for audit and clinical trials: challenges and requirements. J Phys Conf Ser 2013;444:012014.